Relay Therapeutics Inc. Common Stock vs State Street Technology Select Sector SPDR ETF — how do they compare? Relay Therapeutics Inc. Common Stock trades at $18.26 (market cap $3.82B), while State Street Technology Select Sector SPDR ETF trades at $198.77 (market cap $132.55B). The key difference: State Street Technology Select Sector SPDR ETF is far larger — about 34.7× Relay Therapeutics Inc. Common Stock's market cap, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Relay Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Relay Therapeutics Inc. Common Stock for 0 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| RLAY | XLK | |
|---|---|---|
Market Cap | $3.82B | $132.55B |
Volume | 4,332,079 | 9,063,135 |
Sector | Health | Sector/Thematic |
52-Week High | $20.75 | $202.00 |
52-Week Low | $6.03 | $127.49 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $2.93B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XLK trades at $198.68, down 1.35% on the day, with technical indicators showing a bullish overall signal driven by strong moving average support. The ETF maintains neutral oscillators with RSI readings around 60, suggesting balanced momentum. Recent news highlights ongoing investor focus on AI sector dynamics and concentration concerns within XLK's holdings, particularly its heavy chip exposure that may limit diversification benefits despite quarterly rebalancing.
The outlook for XLK remains tied to technology sector performance and AI investment trends, with potential upside from continued enterprise software strength and semiconductor demand. Key risks include interest rate sensitivity, sector concentration, and competitive ETF alternatives offering better risk-adjusted returns. Investors should weigh XLK's cost efficiency against its mega-cap heavy structure when considering technology exposure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →